Detalles de la búsqueda
1.
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.
Clin Infect Dis
; 70(9): 1799-1808, 2020 04 15.
Artículo
Inglés
| MEDLINE | ID: mdl-31400759
2.
Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections.
Antimicrob Agents Chemother
; 64(5)2020 04 21.
Artículo
Inglés
| MEDLINE | ID: mdl-32094127
3.
Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure.
Hepatology
; 66(6): 1794-1804, 2017 12.
Artículo
Inglés
| MEDLINE | ID: mdl-28688129
4.
Proportional exponentiated link transformed hazards (ELTH) models for discrete time survival data with application.
Lifetime Data Anal
; 22(1): 38-62, 2016 Jan.
Artículo
Inglés
| MEDLINE | ID: mdl-25772374
5.
Corifollitropin Alfa Combined With Human Chorionic Gonadotropin in Adolescent Boys With Hypogonadotropic Hypogonadism.
J Clin Endocrinol Metab
; 107(7): 2036-2046, 2022 06 16.
Artículo
Inglés
| MEDLINE | ID: mdl-35275602
6.
Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study.
Open Forum Infect Dis
; 7(3): ofaa054, 2020 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-32154325
Resultados
1 -
6
de 6
1
Próxima >
>>